用法用量 |
Mantle cell lymphoma
PO 560 mg once daily; continue until disease progression or unacceptable toxicity
Chronic lymphocytic leukemia/small lymphocytic lymphoma
PO 420 mg once daily (either as monotherapy or in combination with bendamustine and rituximab or with obinutuzumab); continue until disease progression or unacceptable toxicity
Waldenström macroglobulinemia
PO 420 mg once daily (either as monotherapy or in combination with rituximab); continue until disease progression or unacceptable toxicity
Chronic graft-versus-host disease
PO 420 mg once daily; continue until cGVHD disease progression, recurrence of underlying malignancy, or unacceptable toxicity . When cGVHD treatment is no longer required, discontinue ibrutinib based on medical assessment of patient.
Adjustment for Toxicity
First occurrence
MCL:Restart at 560 mg once daily
CLL/SLL, WM, cGVHD:Restart at 420 mg once daily
Second occurrence
MCL:Restart at 420 mg once daily
CLL/SLL, WM, cGVHD:Restart at 280 mg once daily
Third occurrence
MCL:Restart at 280 mg once daily
CLL/SLL, WM, cGVHD: Restart at 140 mg once daily
Fourth occurrence
MCL, CLL/SLL, WM, cGVHD:Discontinue ibrutinib |
副作用 |
Thrombocytopenia, diarrhea, fatigue, neutropenia, upper respiratory tract infection |